

Anne Zajicek

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1970719/anne-zajicek-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28
papers

1,125
citations

17
h-index

29
g-index

29
ext. papers

1,295
ext. citations

4
avg, IF

3.57
L-index

#	Paper	IF	Citations
28	Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. <i>Journal of Pediatrics</i> , 2018 , 193, 102-108.e1	3.6	21
27	Acute Responses to Diuretic Therapy in Extremely Low Gestational Age Newborns: Results from the Prematurity and Respiratory Outcomes Program Cohort Study. <i>Journal of Pediatrics</i> , 2018 , 197, 42-47.e1	3.6	19
26	Inclusion of pregnant and breastfeeding women in research - efforts and initiatives. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 215-222	3.8	24
25	Reply. <i>Journal of Pediatrics</i> , 2018 , 201, 298	3.6	
24	Pediatric Multiple Organ Dysfunction Syndrome: Promising Therapies. <i>Pediatric Critical Care Medicine</i> , 2017 , 18, S67-S82	3	10
23	Enrollment of Neonates in More Than One Clinical Trial. <i>Clinical Therapeutics</i> , 2017 , 39, 1959-1969	3.5	10
22	Development of Drug Therapies for Newborns and Children: The Scientific and Regulatory Imperatives. <i>Pediatric Clinics of North America</i> , 2017 , 64, 1185-1196	3.6	17
21	Applying Regulatory Science to Develop Safe and Effective Medicines for Neonates: Report of the US Food and Drug Administration First Annual Neonatal Scientific Workshop, October 28-29, 2014. <i>Therapeutic Innovation and Regulatory Science</i> , 2015 , 49, 623-631	1.2	7
20	Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?. <i>Seminars in Perinatology</i> , 2015 , 39, 530-1	3.3	22
19	Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1042-50	3.8	20
18	Evaluation of sodium nitroprusside for controlled hypotension in children during surgery. <i>Frontiers in Pharmacology</i> , 2015 , 6, 136	5.6	9
17	A hemodynamic model to guide blood pressure control during deliberate hypotension with sodium nitroprusside in children. <i>Frontiers in Pharmacology</i> , 2015 , 6, 151	5.6	6
16	Meeting the demand for pediatric clinical trials. <i>Science Translational Medicine</i> , 2014 , 6, 227fs11	17.5	13
15	A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms. <i>AAPS Journal</i> , 2013 , 15, 1072-81	3.7	65
14	Drug Delivery Challenges for the Pediatric Patient: Novel Forms for Consideration 2013 , 576-582		
13	Comparison of a new cobinamide-based method to a standard laboratory method for measuring cyanide in human blood. <i>Journal of Analytical Toxicology</i> , 2013 , 37, 382-5	2.9	5
12	The grand challenges in obstetric and pediatric pharmacology. <i>Frontiers in Pharmacology</i> , 2013 , 4, 170	5.6	2

11	Drug studies in newborns: a therapeutic imperative. <i>Clinics in Perinatology</i> , 2012 , 39, 11-23	2.8	17
10	Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. <i>American Journal of Obstetrics and Gynecology</i> , 2012 , 207, 398.e1-8	6.4	38
9	Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations. <i>Clinical Therapeutics</i> , 2012 , 34, S1-10	3.5	22
8	Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. <i>American Journal of Obstetrics and Gynecology</i> , 2011 , 204, S84-8	6.4	60
7	Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2011 , 57, 252-7	3	37
6	We don't know what we don't study: the case for research on medication effects in pregnancy. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2011 , 157C, 247-50	3.1	30
5	Special challenges in comparative effectiveness research on children's and adolescents' health. <i>Health Affairs</i> , 2010 , 29, 1849-56	7	17
4	Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy. <i>Clinical and Translational Science</i> , 2009 , 2, 11-4	4.9	4
3	The National Institutes of Health and the Best Pharmaceuticals for Children Act. <i>Paediatric Drugs</i> , 2009 , 11, 45-7	4.2	22
2	Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. <i>Journal of Pain</i> , 2008 , 9, 771-83	5.2	585
1	Gaps in knowledge in treating pregnant women. <i>Gender Medicine</i> , 2006 , 3, 169-82		43